EyePoint Pharmaceuticals, Inc.’s EYPT share price has dipped by 15.13%, which has investors questioning if this is right time to buy.

and findings from a clinical trial focused on non-proliferative diabetic retinopathy. Ocular is utilizing its proprietary bioresorbable hydrogel technology, ELUTYX™, in its ongoing trials ...

James analyst Dane Leone maintained a Strong Buy rating and a $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), aligning with the broader analyst consensus. According to InvestingPro data, ...

BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to ...

Ferroptosis is associated with various diseases, but the relationship with diabetic retinopathy(DR) is less studied. DR is one of the complications of diabetes mellitus and has a severe impact on ...

Undernutrition remains a major issue in global health. Low protein-energy consumption, results in stunting, wasting and/or underweight, three deleterious forms of malnutrition that affect roughly 200 ...